AZRX - AzurRx BioPharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

AzurRx BioPharma, Inc.

Downstate Biotechnology Incubator
Suite 304 760 Parkside Avenue
Brooklyn, NY 11226
United States

Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. James R. Sapirstein R.Ph., M.B.A.CEO, Pres & Non-Independent Director443.61kN/A1961
Dr. James E. PenningtonChief Medical Officer330kN/A1943
Mr. Martin KrusinSr. VP of Corp. Devel.N/AN/AN/A
Mr. Daniel H. SchneidermanChief Financial OfficerN/AN/A1978
Dr. Mathieu Schué Ph.D.Head of LaboratoryN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of therapeutic proteins under development, including MS1819-SD, a yeast derived recombinant lipase for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase enzyme combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea, as well as AZX1103, a b-lactamase enzyme combination. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

Corporate Governance

AzurRx BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.